中国中药杂志

2020, v.45(14) 3307-3315

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

真实世界中丹参川芎嗪注射液治疗脑梗死人群的临床用药特征研究
Study on clinical characteristics of Danshen Chuanxiongqin Injection in treatment of cerebral infarction in real world

郭晓晨;高阳;谢雁鸣;孙粼希;徐鸿燕;庄严;
GUO Xiao-chen;GAO Yang;XIE Yan-ming;SUN Lin-xi;XU Hong-yan;ZHUANG Yan;Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences;Xiyuan Hospital, China Academy of Chinese Medical Sciences;School of Statistics, Renmin University of China;Naval PLA General Hospital;

摘要(Abstract):

该研究对使用丹参川芎嗪注射液治疗脑梗死人群的临床特征和联合用药规律进行分析。选取全国20家三级甲等医院HIS数据库中使用丹参川芎嗪注射液的2 857例脑梗死患者的住院信息,采用描述分析、Apriori算法建立模型,探究丹参川芎嗪注射液治疗脑梗死的临床特征及联合用药规律。结果显示,使用丹参川芎嗪注射液的脑梗死患者中,65岁以上患者共1 727例,占69.61%,男性1 610例,占63.59%。治疗上与降脂药、抗凝溶栓及抗血小板药、脑代谢功能促进剂、血管扩张药等西药,以及中药活血化瘀剂、清热剂、祛痰剂等联合使用较为常见。与丹参川芎嗪注射液联合使用频数最高的西药是阿司匹林肠溶片(1 528例,53.48%),中药是醒脑静注射液(378例,13.23%);其中与丹参川芎嗪注射液最常用的西药合并用药类别是抗凝溶栓及抗血小板药,使用率达83.48%,最常用的中药合并用药类别是活血化瘀剂,使用率达63.49%。为了更深入地探索丹参川芎嗪注射液的合并用药规律,对使用丹参川芎嗪注射液的脑梗死患者合并药物进行关联分析。临床联合2种西药时,最常联用阿托伐他汀钙胶囊+脑蛋白水解物注射液组合,支持度27.10%;联合3种西药时,最常联用硫酸氢氯吡格雷片+阿托伐他汀钙胶囊+脑蛋白水解物注射液组合,支持度15.90%。结果表明,使用丹参川芎嗪注射液的脑梗死患者以老年男性为主,常合并高血压病、冠心病、糖尿病等基础疾病;丹参川芎嗪注射液的临床应用与指南基本相符,其在治疗脑梗死时常与西药抗凝溶栓及抗血小板药、中药活血化瘀剂等药理作用相似的药物联合使用,且对合并有其他疾病的脑梗死患者有辅助治疗作用,为临床用药提供指导。
In this study, the clinical characteristics and drug combination rules of Danshen Chuanxiongqin Injection in the treatment of patients with cerebral infarction were analyzed. The inpatient information of 2 857 patients of cerebral infarction treated with Danshen Chuanxiongqin Injection in HIS database of 20 grade Ⅲ class A hospitals in China was collected, and a model was established by description analysis and Apriori algorithm, in order to explore the clinical characteristics and drug combination rules of Danshen Chuan-xiongqin Injection in the treatment of cerebral infarction. The results showed that among patients of cerebral infarction treated with Danshen Chuanxiongqin Injection, 1 727 patients were older than 65 years old, accounting for 69.61%, and 1 610 were males, accounting for 63.59%. Commonly used drugs included lipid-lowering agents, anticoagulant thrombolytic agents, antiplatelet agents, stimulants of brain metabolism, vasodilators and other Western drugs, as well as traditional Chinese medicines, such as blood-activating agents, heat-clearing agents and expectorant agents. The Western medicine with the highest use frequency in combination with Danshen Chuan-xiongqin Injection was aspirin enteric-coated tablets(1 528 cases, 53.48%). The traditional Chinese medicine with the highest use frequency in combination with Danshen Chuanxiongqin Injection was Xingnaojing Injection, with a total of 378 cases, accounting for 13.23%. Among them, the most commonly used Western drugs combined with Danshen Chuanxiongqin Injection were anticoagulant thrombolytic and antiplatelet drugs, with a usage rate as high as 83.48%. In order to further explore the drug combination rules of Danshen Chuanxiongqin Injection, the association analysis of drug combination in patients of cerebral infarction treated with Danshen Chuanxiongqin Injection was carried out. In clinical combination of two Western drugs, Atorvastatin Calcium Capsules+Cerebral Proteolytic Injection were the most common combination, with a support of 27.10%. In clinical combination with 3 Western drugs, Clopidogrel Bisulfate Tablets+Atorvastatin Calcium Capsules+Cerebral Proteolytic Injection were most commonly used, with a support of 15.90%. The results showed that the patients of cerebral infarction treated with Danshen Chuanxiongqin Injection were mainly elderly males, and often complicated with hypertension, coronary heart disease, diabetes and other basic diseases. The clinical application of Danshen Chuanxiongqin Injection was principally in line with the guidelines. In the treatment of cerebral infarction, it was often combined with Western medicine anticoagulant thrombolysis, antiplatelet drugs, traditional Chinese medicine blood-activating and stasis-dissolving prescription and other drugs with similar pharmacological effects, with an auxiliary therapeutic effect on patients of cerebral infarction complicated with other diseases, and can provide guidance for clinical medication.

关键词(KeyWords): 真实世界;脑梗死;丹参川芎嗪注射液;用药特征;关联规则
real world;cerebral infarction;Danshen Chuanxiongqin Injection;medication characteristics;association rules

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划项目(2018YFC1707400)

作者(Author): 郭晓晨;高阳;谢雁鸣;孙粼希;徐鸿燕;庄严;
GUO Xiao-chen;GAO Yang;XIE Yan-ming;SUN Lin-xi;XU Hong-yan;ZHUANG Yan;Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences;Xiyuan Hospital, China Academy of Chinese Medical Sciences;School of Statistics, Renmin University of China;Naval PLA General Hospital;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享